Skip to main content
Year archive

Medivir — 2023 filings

All 33 regulatory filings released by Medivir (MVIR) in 2023, sourced directly from the official regulator.

33 Filings
2023 Period
2023 filings (33)
Filing Released Lang
Medivir offentliggör utfallet i företrädesemissionen
Capital/Financing Update
2023-12-22 Swedish
Medivir announces the outcome of the rights issue
Capital/Financing Update
2023-12-22 English
Medivir publishes prospectus in connection with the rights issue
Capital/Financing Update
2023-12-06 English
Medivir offentliggör prospekt med anledning av företrädesemission
Share Issue/Capital Change
2023-12-06 Swedish
Kommuniké från extra bolagsstämma i Medivir AB (publ)
Share Issue/Capital Change
2023-12-01 Swedish
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
AGM Information
2023-12-01 English
Notice of Extraordinary General Meeting in Medivir AB (publ)
AGM Information
2023-11-07 English
Kallelse till extra bolagsstämma i Medivir AB (publ)
AGM Information
2023-11-07 Swedish
Medivir beslutar om en partiellt garanterad företrädesemission motsvarande cirka 148 MSEK
Capital/Financing Update
2023-11-07 Swedish
Medivir announces a partially guaranteed rights issue of approximately SEK 148 million
Share Issue/Capital Change
2023-11-07 English
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-10-27 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-10-27 English
Förändring i Medivirs styrelse
Board/Management Information
2023-10-20 Swedish
Change in Medivir's Board of Directors
Board/Management Information
2023-10-20 English
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima
Earnings Release FY 2023
2023-09-04 English
Medivir rapporterar lovande interimsdata, som inkluderar ett komplett tumörsvar, i fas 1b/2a HCC-studien med fostrox i kombination med Lenvima
Earnings Release FY 2023
2023-09-04 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-18 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-18 English
Change in the number of shares and votes in Medivir AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2023-05-31 English
Förändring av antal aktier och röster i Medivir AB (publ)
Share Issue/Capital Change
2023-05-31 Swedish
Verkställande av årsstämmans beslut om avskaffande av aktieslag i Medivir AB (publ)
Share Issue/Capital Change
2023-05-04 Swedish
Execution of the annual general meeting’s resolution on the removal of share class in Medivir AB (publ)
AGM Information
2023-05-04 English
Beslut vid årsstämma i Medivir den 4 maj 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-04 Swedish
Resolutions at the Annual General Meeting in Medivir on 4 May 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-04 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-27 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-27 English
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-04-04 Swedish
Notice of Annual General Meeting of Medivir AB (publ)
AGM Information
2023-03-31 English
Kallelse till årsstämma i Medivir AB (publ)
AGM Information
2023-03-31 Swedish
Medivir har fastställt den rekommenderade fas 2-dosen för fostrox i kombination med Lenvima vid HCC
Regulatory Filings
2023-02-20 Swedish
Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC
Regulatory Filings
2023-02-20 English
Interim / Quarterly Report 2022
Interim / Quarterly Report FY 2022
2023-02-15 Swedish
Audit Report / Information 2022
Audit Report / Information FY 2022
2023-02-15 English